84年鼠女哪年财运最旺,857comvvv色九欧美激情|85PO_87国产精品欲av国产av资源

[1]李中萬,徐紹俊,楊廣鋼,等.健腎方聯(lián)合碳酸鈣D3咀嚼片(Ⅱ) 治療絕經(jīng)后骨質(zhì)疏松癥腎陽虛證[J].中醫(yī)正骨,2018,30(08):11-15.
　LI Zhongwan,XU Shaojun,YANG Guanggang,et al.Oral application of Jianshen Fang(健腎方)and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ)for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(08):11-15.
點(diǎn)擊復(fù)制

健腎方聯(lián)合碳酸鈣D3咀嚼片(Ⅱ) 治療絕經(jīng)后骨質(zhì)疏松癥腎陽虛證()
分享到：

《中醫(yī)正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第30卷
期數(shù):
2018年08期
頁碼:
11-15
欄目:
臨床研究
出版日期:
2018-08-20

文章信息/Info

Title:
Oral application of Jianshen Fang(健腎方)and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ)for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome
作者:
李中萬; 徐紹俊; 楊廣鋼; 姚麗云; 付小勇; 潘永雄
廣東省廣州市正骨醫(yī)院,廣東 廣州 510045
Author(s):
LI Zhongwan; XU Shaojun; YANG Guanggang; YAO Liyun; FU Xiaoyong; PAN Yongxiong
Guangzhou Orthopedic Hospital,Guangzhou 510045,Guangdong,China
關(guān)鍵詞:
骨質(zhì)疏松; 絕經(jīng)后;  腎陽虛;  健腎方;  骨密度;  雌二醇;  骨保護(hù)素;  胰島素樣生長因子Ⅰ
Keywords:
osteoporosis;  postmenopausal;  kidney-yang deficiency;  Jianshen Fang;  bone density;  estradiol;  osteoprotegerin;  insulin-like growth factor I
摘要:
觀察健腎方聯(lián)合碳酸鈣D3咀嚼片(Ⅱ)治療絕經(jīng)后骨質(zhì)疏松癥(postmenopausal osteoporosis,PMOP)腎陽虛證的臨床療效和安全性。方法:選取80例符合要求的PMOP腎陽虛證患者,隨機(jī)分為2組,每組40例。健腎方組采用口服健腎方聯(lián)合碳酸鈣D3咀嚼片(Ⅱ)治療,阿侖膦酸鈉組采用口服阿侖膦酸鈉片聯(lián)合碳酸鈣D3咀嚼片(Ⅱ)治療,共治療6個月。分別于治療前和治療結(jié)束后測定患者的骨密度、疼痛程度、血清雌二醇(Estradiol,E2)、骨保護(hù)素和胰島素樣生長因子Ⅰ(insulin-like growth factor Ⅰ, IGF-Ⅰ)含量,觀察不良反應(yīng)的發(fā)生情況。結(jié)果:健腎方組2例出現(xiàn)肝功能指標(biāo)異常,2例出現(xiàn)腎功能指標(biāo)異常; 阿侖膦酸鈉組1例出現(xiàn)肝功能指標(biāo)異常,1例出現(xiàn)腎功能指標(biāo)異常。對于出現(xiàn)不良反應(yīng)的患者均立即停止使用當(dāng)前藥物,給予護(hù)肝及保護(hù)腎功能等對癥處理后,患者的肝腎功能指標(biāo)均在2周內(nèi)恢復(fù)至正常范圍。2組患者的不良反應(yīng)發(fā)生率比較,差異無統(tǒng)計學(xué)意義(χ2=0.180,P=0.671)。治療前2組患者的骨密度比較,差異無統(tǒng)計學(xué)意義(t=1.014,P=0.314); 治療結(jié)束后2組患者的骨密度均較治療前增加(-2.69±0.12,-2.09±0.22,t=14.343,P=0.000; -2.72±0.13,-2.37±0.09,t=14.038,P=0.000),健腎方組的骨密度高于阿侖膦酸鈉組(t=6.931,P=0.000)。治療前2組患者的疼痛視覺模擬量表(visual analogue scale,VAS)評分比較,差異無統(tǒng)計學(xué)意義(t=0.465,P=0.644); 治療結(jié)束后2組患者的疼痛VAS評分均較治療前降低[(4.53±0.94)分,(2.33±0.68)分,t=11.366,P=0.000;(4.42±1.03)分,(3.21±0.87)分,t=5.522,P=0.000],健腎方組的VAS評分低于阿侖膦酸鈉組(t=4.841,P=0.000)。治療前2組患者的血清E2含量比較,差異無統(tǒng)計學(xué)意義(t=0.511,P=0.611); 治療結(jié)束后健腎方組的血清E2含量較治療前升高[(50.91±6.24)pmol·L-1,(62.88±9.02)pmol·L-1,t=6.546,P=0.000]; 阿侖膦酸鈉組血清E2含量與治療前相比,差異無統(tǒng)計學(xué)意義[(50.17±6.31)pmol·L-1,(50.88±8.16)pmol·L-1,t=0.425,P=0.672]; 治療結(jié)束后,健腎方組的血清E2含量高于阿侖膦酸鈉組(t=6.006,P=0.000)。治療前2組患者的血清骨保護(hù)素含量比較,差異無統(tǒng)計學(xué)意義(t=0.348,P=0.729); 治療結(jié)束后2組患者的血清骨保護(hù)素含量均較治療前升高[(140.76±14.97)pg·mL-1,(160.18±15.70)pg·mL-1,t=5.371,P=0.000;(139.55±14.99)pg·mL-1,(146.68±15.68)pg·mL-1,t=2.027,P=0.046],健腎方組的血清骨保護(hù)素含量高于阿侖膦酸鈉組(t=3.701,P=0.000)。治療前2組患者的血清IGF-Ⅰ含量比較,差異無統(tǒng)計學(xué)意義(t=0.839,P=0.404); 治療結(jié)束后2組患者的血清IGF-Ⅰ含量均較治療前升高[(25.19±8.34)μg·L-1,(35.81±9.48)μg·L-1,t=5.042,P=0.000;(23.53±8.74)μg·L-1,(28.87±10.29)μg·L-1,t=2.440,P=0.017],健腎方組的血清IGF-Ⅰ含量高于阿侖膦酸鈉組(t=3.012,P=0.004)。結(jié)論:健腎方聯(lián)合碳酸鈣D3咀嚼片(Ⅱ)能提高PMOP腎陽虛證患者血清E2、骨保護(hù)素及IGF-Ⅰ含量,增加患者的骨密度、減輕疼痛程度,其效果優(yōu)于阿侖膦酸鈉片聯(lián)合碳酸鈣D3咀嚼片(Ⅱ)治療,而且具有較高的安全性。
Abstract:
To observe the clinical curative effects and safety of oral application of Jianshen Fang(健腎方,JSF)and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ)for treatment of postmenopausal osteoporosis(PMOP)with kidney-yang deficiency syndrome.Methods:Eighty patients with kidney-yang deficiency type PMOP were enrolled in the study and randomly divided into 2 groups,40 cases in each group,and were treated with oral application of JSF and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ)(JSFgroup)and oral application of alendronate sodium tablets and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ)(alendronate sodium group)respectively for consecutive 6 months.Bone density,pain degree and serum contents of Estradiol(E2),osteoprotegerin(OPG)and insulin-like growth factor Ⅰ(IGF-Ⅰ)were measured and compared between the 2 groups before treatment and after the end of the treatment respectively,and the incidence rate of adverse reactions was observed.Results:Abnormal liver function indexes were found in 2 patients in JSF group and 1 patient in alendronate sodium group,and abnormal kidney function indexes were found in 2 patients in JSF group and 1 patient in alendronate sodium group.The drugs which caused adverse effects were withdrew immediately and liver and kidney protective agents were used,and the liver and kidney function recovered from injury 2 weeks later.There was no statistical difference in the incidence rate of adverse reactions between the 2 groups(χ2=0.180,P=0.671).There was no statistical difference in the bone density between the 2 groups before the treatment(t=1.014,P=0.314).The bone density increased after the end of the treatment compared to pretreatment in the 2 groups(-2.69+/-0.12 vs -2.09+/-0.22,t=14.343,P=0.000; -2.72+/-0.13 vs -2.37+/-0.09,t=14.038,P=0.000),and was higher in JSF group compared to alendronate sodium group(t=6.931,P=0.000).There was no statistical difference in pain visual analogue scale(VAS)scores between the 2 groups before the treatment(t=0.465,P=0.644).The pain VAS scores decreased after the end of the treatment compared to pretreatment in the 2 groups(4.53+/-0.94 vs 2.33+/-0.68 points,t=11.366,P=0.000; 4.42+/-1.03 vs 3.21+/-0.87 points,t=5.522,P=0.000),and was lower in JSF group compared to alendronate sodium group(t=4.841,P=0.000).There was no statistical difference in serum contents of E2 between the 2 groups before the treatment(t=0.511,P=0.611).The serum contents of E2 increased after the end of the treatment compared to pretreatment in JSF group(50.91+/-6.24 vs 62.88+/-9.02 pmol/L,t=6.546,P=0.000).There was no statistical difference in serum contents of E2 between pre-treatment and post-treatment in alendronate sodium group(50.17+/-6.31 vs 50.88+/-8.16 pmol/L,t=0.425,P=0.672).The serum contents of E2 were higher in JSF group compared to alendronate sodium group after the end of the treatment(t=6.006,P=0.000).There was no statistical difference in serum contents of OPG between the 2 groups before the treatment(t=0.348,P=0.729).The serum contents of OPG increased after the end of the treatment compared to pretreatment in the 2 groups(140.76+/-14.97 vs 160.18+/-15.70 pg/mL,t=5.371,P=0.000; 139.55+/-14.99 vs 146.68+/-15.68 pg/mL,t=2.027,P=0.046),and were higher in JSF group compared to alendronate sodium group(t=3.701,P=0.000).There was no statistical difference in serum contents of IGF-Ⅰbetween the 2 groups before the treatment(t=0.839,P=0.404).The serum contents of IGF-Ⅰincreased after the end of the treatment compared to pretreatment in the 2 groups(25.19+/-8.34 vs 35.81+/-9.48 μg/L,t=5.042,P=0.000; 23.53+/-8.74 vs 28.87+/-10.29 μg/L,t=2.440,P=0.017),and were higher in JSF group compared to alendronate sodium group(t=3.012,P=0.004).Conclusion:Oral application of JSF and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ)can increase the serum contents of E2,OPG and IGF-Ⅰand improve bone density and alleviate pain in patients with kidney-yang deficiency type PMOP,and its curative effect is better than that of oral application of alendronate sodium tablets and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ),moreover,it has high safety.

參考文獻(xiàn)/References:

[1] BLACK DM,ROSEN CJ.Clinical practice.Postmenopausal osteoporosis[J].N Engl J Med,2016,374(3):254-262.
[2] 徐紹俊,黃建烽,邵敏,等.雌激素受體α基因甲基化與骨質(zhì)疏松關(guān)系的研究進(jìn)展[J]. 中國骨質(zhì)疏松雜志, 2017, 23(3):388-391.
[3] MANOLAGAS SC,O'BRIEN CA,ALMEIDA M.The role of estrogen and androgen receptors in bone health and disease[J].Nat Rev Endocrinol,2013,9(12):699-712.
[4] 劉剛,唐瑭,劉晶晶.阿侖膦酸鈉聯(lián)合鈣爾奇D治療老年骨質(zhì)疏松62例[J].中國老年學(xué)雜志,2012,32(18):4070-4071.
[5] 羅建,聶桂峰,黃小虎,等.固力康聯(lián)合鈣爾奇D在骨質(zhì)疏松癥合并股骨粗隆間骨折治療中的療效及其對骨代謝指標(biāo)的影響[J].安徽醫(yī)藥,2017,21(6):1101-1105.
[6] 中國老年學(xué)學(xué)會骨質(zhì)疏松委員會中醫(yī)藥與骨病學(xué)科組.中醫(yī)藥防治原發(fā)性骨質(zhì)疏松癥專家共識(2015)[J].中國骨質(zhì)疏松雜志,2015,21(9):1023-1028.
[7] 徐紹俊,黃建烽,邵敏,等.補(bǔ)腎方劑對絕經(jīng)后骨質(zhì)疏松癥大鼠的影響及其作用機(jī)制研究[J].中藥新藥與臨床藥理,2017,28(5):588-593.
[8] CRANDALL CJ,NEWBERRY SJ,DIAMANT A,et al.Comparative effectiveness of pharmacologic treatments to prevent fractures:an updated systematic review[J].Ann Intern Med,2014,161(10):711-723.
[9] 趙文昌,宋麗軍,溫凱航,等.淫羊藿抗骨質(zhì)疏松癥的研究進(jìn)展[J].中醫(yī)藥導(dǎo)報,2012,9(25):20-21.
[10] 周菊峰,黃蘭芳,胡偉,等.氣相色譜/質(zhì)譜和化學(xué)計量學(xué)解析法用于千斤拔揮發(fā)性成分的分析[J].藥物分析雜志,2011,31(7):1308-1312.
[11] 徐林,傅忠國,易斌,等.阿侖膦酸鈉治療絕經(jīng)后骨質(zhì)疏松療效及安全性分析[J].中國藥房,2000,11(1):33-34.
[12] 周漢華,劉曉龍,錢海兵,等.不同寄主上的桑寄生藥材毒性的比較研究[J].中國實驗方劑學(xué)雜志,2013,19(24):274-277.

相似文獻(xiàn)/References:

[1]李林軍.應(yīng)用膨脹式椎弓根螺釘內(nèi)固定治療合并骨質(zhì)疏松的 胸腰椎退行性疾病[J].中醫(yī)正骨,2015,27(08):49.
[2]李學(xué)朋,朱立國.骨疏康膠囊對去卵巢大鼠骨小梁的影響[J].中醫(yī)正骨,2015,27(12):12.
　LI Xuepeng,ZHU Liguo.Effect of Gushukang Jiaonang(骨疏康膠囊)on bone trabecula in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(08):12.
[3]陳冠軍,陳揚(yáng),莊汝杰.可灌注骨水泥椎弓根螺釘系統(tǒng) 在老年腰椎疾患手術(shù)中的應(yīng)用[J].中醫(yī)正骨,2015,27(02):40.
[4]王丹輝,賁越,韓梅.林蛙油治療絕經(jīng)后骨質(zhì)疏松癥的臨床研究[J].中醫(yī)正骨,2014,26(01):27.
　Wang Danhui*,Ben Yue,Han Mei..Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(08):27.
[5]黃建華,黃建武,李慧輝,等.加味左歸丸對絕經(jīng)后骨質(zhì)疏松癥肝腎不足證 患者骨密度的影響[J].中醫(yī)正骨,2013,25(11):19.
　Huang Jianhua*,Huang Jianwu,Li Huihui,et al.Effect of JIAWEI ZUOGUI pill on bone mineral density in postmenopausal osteoporosis patients with deficiency of liver and kidney[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(08):19.
[6]項旻,楊虹,林愛菊,等.絕經(jīng)后2型糖尿病患者骨質(zhì)疏松與血微量元素的關(guān)系研究[J].中醫(yī)正骨,2013,25(12):20.
　Xiang Min*,Yang Hong,Lin Aiju,et al.Clinical study on the relationship between osteoporosis and serum trace elements levels in postmenopausal women with type 2 diabetes[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(08):20.
[7]史曉林,李春雯,張志強(qiáng).弱陽離子磁珠分離技術(shù)和基質(zhì)輔助激光解吸電離飛行時間質(zhì)譜技術(shù)在原發(fā)性Ⅰ型骨質(zhì)疏松癥血清標(biāo)志蛋白篩選中的應(yīng)用[J].中醫(yī)正骨,2014,26(03):5.
　Shi Xiaolin*,Li Chunwen,Zhang Zhiqiang..Application of magnetic beads based weak cation exchange separation technology and matrix-assisted laser desorption-ionization time of flight mass spectrometry technology in screening serum protein markers of primary type-Ⅰ osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(08):5.
[8]李明,徐明雄,馮左基,等.自擬壯骨方治療絕經(jīng)后骨質(zhì)疏松癥的療效及作用機(jī)制研究[J].中醫(yī)正骨,2014,26(09):21.
　Li Ming*,Xu Mingxiong,Feng Zuoji,et al.Study on the curative effect and mechanism of action of self-made ZHUANGGU decoction in treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(08):21.
[9]陳俊杰,李晴晴,夏瑢.脂代謝及血清內(nèi)脂素水平與絕經(jīng)后骨質(zhì)疏松癥的 相關(guān)性研究[J].中醫(yī)正骨,2012,24(04):16.
　CHEN Jun-jie*,LI Qing-qing,XIA Rong.*.Study on the correlations between the levels of lipid metabolism and serum visfatin and postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(08):16.
[10]許超,肖魯偉,吳承亮.絕經(jīng)后女性骨質(zhì)疏松癥辨證分型與抑郁焦慮的關(guān)系研究[J].中醫(yī)正骨,2011,23(12):3.
　XU Chao*,XIAO Lu-wei,WU Cheng-liang.*.Study on the relationship between the syndrome differ classification and the depression and anxiety for the postmenopausal women with osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2011,23(08):3.
[11]韓艷,溫利平,劉娜,等.補(bǔ)腎活血方對去卵巢大鼠骨代謝及骨密度的影響[J].中醫(yī)正骨,2015,27(12):7.
　HAN Yan,WEN Liping,LIU Na,et al.Effect of Bushen Huoxue Fang(補(bǔ)腎活血方)on bone metabolism and bone mineral density in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(08):7.
[12]歐國峰,劉鑫,董博,等.絕經(jīng)后骨質(zhì)疏松癥的免疫學(xué)研究進(jìn)展[J].中醫(yī)正骨,2016,28(08):70.
[13]施振宇,劉鐘,陳文亮,等.中醫(yī)綜合療法防治絕經(jīng)后骨量減少的多中心臨床研究[J].中醫(yī)正骨,2017,29(04):1.
　SHI Zhenyu,LIU Zhong,CHEN Wenliang,et al.A multicenter clinical study of complex therapy of traditional Chinese medicine for prevention and treatment of postmenopausal osteopenia[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(08):1.
[14]梁文娜,李西海,李燦東.血清microRNA與絕經(jīng)后骨質(zhì)疏松癥腎虛證的關(guān)系[J].中醫(yī)正骨,2017,29(10):53.
[15]梁文娜,李西海,胡柳,等.二至丸抑制絕經(jīng)后骨質(zhì)疏松大鼠骨代謝紊亂的作用機(jī)制研究[J].中醫(yī)正骨,2017,29(11):1.
　LIANG Wenna,LI Xihai,HU Liu,et al.Study on mechanism of action of Erzhi Wan(二至丸)in inhibiting bone metabolism disorder in rats with postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(08):1.
[16]劉晨,李興勇,姚興璋,等.絕經(jīng)后骨質(zhì)疏松癥的流行病學(xué)概況及發(fā)病機(jī)制研究進(jìn)展[J].中醫(yī)正骨,2018,30(03):52.
[17]楊依然,劉鐘,毛一凡,等.酪蛋白激酶-2相互作用蛋白1基于磷脂酰肌醇3-激酶/蛋白激酶B/哺乳動物雷帕霉素靶蛋白通路參與絕經(jīng)后骨質(zhì)疏松癥發(fā)生發(fā)展過程中細(xì)胞自噬的機(jī)制[J].中醫(yī)正骨,2018,30(04):59.
[18]曹俊青,鄭劍南,張麟.右歸丸聯(lián)合阿侖膦酸鈉口服治療絕經(jīng)后骨質(zhì)疏松癥腎陽虛證的臨床研究[J].中醫(yī)正骨,2018,30(05):20.
　CAO Junqing,ZHENG Jiannan,ZHANG Lin.A clinical study of oral application of Yougui Wan(右歸丸)and alendronate sodium for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(08):20.
[19]趙凡,劉全,吳連國.口服強(qiáng)骨飲聯(lián)合碳酸鈣D3片治療絕經(jīng)后骨質(zhì)疏松癥的臨床研究[J].中醫(yī)正骨,2019,31(04):26.
　ZHAO Fan,LIU Quan,WU Lianguo.Oral applications of Qianggu Yin(強(qiáng)骨飲)and calcium carbonate and Vitamin D3 tablets for treatment of postmenopausal osteoporosis:a clinical study[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2019,31(08):26.
[20]史曉林,楊依然,劉鐘,等.基于蛋白質(zhì)組學(xué)方法分析絕經(jīng)后骨質(zhì)疏松癥全血差異蛋白[J].中醫(yī)正骨,2019,31(06):7.
　SHI Xiaolin,YANG Yiran,LIU Zhong,et al.Analysis of proteins which are differentially expressed in whole blood of patients with postmenopausal osteoporosis using proteomics approach[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2019,31(08):7.

備注/Memo

備注/Memo:
基金項目:廣東省中醫(yī)藥局科研課題(20172116) 通訊作者:徐紹俊 E-mail:[email protected]
更新日期/Last Update: 2018-08-31